India

COVID-19 Coronavirus Pandemic – Latest Media Coverage

AbbVie

Latest news and video coverage curated from trusted media outlets


0 shares	Share Tweet Save Post Send


ABBV \| AbbVie Inc. \| Quick Take Welcome to another episode of A to Z Investing! In this short [ABBV \| AbbVie Inc \| Quick Take] video , [BeachBum Trading] provides insight into ABBV, a dividend paying stock for those interested in.. Credit: Rumble Duration: 00:59Published on January 18, 2024

You Might Like

Worldwide: Pharma – Strong Year Ahead - Herbert Smith Freehills After a relatively flat start, activity picked up in the second half of the year with a flurry of sizeable transactions announced including AbbVie's acquisitions of Cerevel and ImmunoGen... Mondaq - Published 2 weeks ago
China: Chinese Patent Office Hands Down Key Ruling On Pharma Patent Requirements - Rouse The Patent Re-examination Board of China's National Intellectual Property Administration (PRB) recently issued a decision to invalidate two "orange book" patents owned by AbbVie. Mondaq - Published on March 15, 2024
United States: First High-Concentration Humira® Interchangeable, Alvotech And Teva's Simlandi®, Approved In The U.S. - Venable LLP On February 23, 2024, the FDA approved Alvotech and Teva's Simlandi® (adalimumab-ryvk) as biosimilar to and interchangeable with AbbVie's Humira® (adalimumab). Simlandi® is the tenth Humira... Mondaq - Published on March 11, 2024

Canada: LUMIGAN RC Formulation Patent Found Valid And Infringed - Smart & Biggar In a patent infringement action brought by Allergan and AbbVie under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (Regulations)... Mondaq - Published on February 2, 2024
Canada: Eye Spy Prior Art: Obviousness Is Central To Decision In Allergan V Juno, 2023 FC 1686 - Gowling WLG Allergan and Abbvie brought this action under the PM(NOC) Regulations, seeking to prevent the issuance of a Notice of Compliance for Juno Pharmaceuticals' generic version of Allergan's... Mondaq - Published on January 25, 2024
United States: Coherus And AbbVie File Dueling Motions For Injunctive Relief Relating To Coherus's HUMIRA Biosimilar - Goodwin Procter LLP Our readers may recall that ten HUMIRA biosimilars have been licensed to launch, with Amgen's AMJEVITA the only one to launch to date and nine others set to launch starting in July 2023. Mondaq - Published on June 29, 2023

United States: AbbVie's Q322 Earnings Call Highlights Oncoming Adalimumab Biosimilar Competition - Goodwin Procter LLP Last week, AbbVie held its third quarter 2022 earnings conference call, which included considerable discussion of forthcoming competition with biosimilars to HUMIRA (adalimumab) in 2023. Mondaq - Published on November 7, 2022
Canada: NOC Regulations Do Not Apply To Biosimilars When Reference Products Are Not Marketed - Borden Ladner Gervais LLP The Federal Court recently denied AbbVie's application for judicial review of two decisions of the Minister of Health (the Minister) relating to JAMP Pharma's SIMLANDI product... Mondaq - Published on September 8, 2022
AbbVie in India* receives Great Place to Work Certification newKerala.com - Published on December 24, 2021
Great Place to Work Announces the Best Workplaces in Asia™ 2021 Representing 3.3 plus Million Employee Experiences Great Place to Work^, the global authority on workplace culture, surveyed over 3.3 million employees from across 16 diverse countries and cultures in Asia and the Middle East to determine the Best.. NewsVoir - Published on July 22, 2021